Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:CPRX NASDAQ:GHRS NYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$81.26+2.5%$69.88$49.00▼$86.53$2.52B-1.4657,851 shs74,400 shsCPRXCatalyst Pharmaceuticals$21.26+4.7%$20.21$19.05▼$26.58$2.49B0.791.56 million shs1.35 million shsGHRSGH Research$14.50+8.9%$13.21$6.72▼$20.50$693.02M0.97329,360 shs544,982 shsOGNOrganon & Co.$9.55-0.1%$9.93$8.01▼$19.05$2.49B0.633.72 million shs2.89 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+2.52%+4.10%+21.65%+33.23%+46.55%CPRXCatalyst Pharmaceuticals+4.68%+4.27%+7.59%-0.89%+0.38%GHRSGH Research+8.86%+10.10%+10.60%-15.94%+104.23%OGNOrganon & Co.-0.26%-6.85%-8.06%-0.99%-47.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$81.26+2.5%$69.88$49.00▼$86.53$2.52B-1.4657,851 shs74,400 shsCPRXCatalyst Pharmaceuticals$21.26+4.7%$20.21$19.05▼$26.58$2.49B0.791.56 million shs1.35 million shsGHRSGH Research$14.50+8.9%$13.21$6.72▼$20.50$693.02M0.97329,360 shs544,982 shsOGNOrganon & Co.$9.55-0.1%$9.93$8.01▼$19.05$2.49B0.633.72 million shs2.89 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+2.52%+4.10%+21.65%+33.23%+46.55%CPRXCatalyst Pharmaceuticals+4.68%+4.27%+7.59%-0.89%+0.38%GHRSGH Research+8.86%+10.10%+10.60%-15.94%+104.23%OGNOrganon & Co.-0.26%-6.85%-8.06%-0.99%-47.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 2.50Moderate Buy$96.0018.14% UpsideCPRXCatalyst Pharmaceuticals 3.00Buy$33.2056.16% UpsideGHRSGH Research 2.70Moderate Buy$30.38109.48% UpsideOGNOrganon & Co. 2.50Moderate Buy$17.3381.54% UpsideCurrent Analyst Ratings BreakdownLatest GHRS, BLTE, OGN, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025GHRSGH ResearchNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.0010/13/2025GHRSGH ResearchNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.0010/8/2025BLTEBelite BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CPRXCatalyst PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025GHRSGH ResearchWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OGNOrganon & Co.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025BLTEBelite BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CPRXCatalyst PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025GHRSGH ResearchWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OGNOrganon & Co.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/16/2025BLTEBelite BioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/ACPRXCatalyst Pharmaceuticals$558.50M4.66$2.56 per share8.30$6.10 per share3.49GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AOGNOrganon & Co.$6.40B0.39$4.92 per share1.94$1.83 per share5.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$36.14M-$1.55N/AN/AN/AN/A-34.90%-33.56%11/11/2025 (Estimated)CPRXCatalyst Pharmaceuticals$163.89M$1.6512.889.980.8137.36%40.78%35.36%11/5/2025 (Estimated)GHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)OGNOrganon & Co.$864M$2.693.552.550.8611.15%163.88%6.99%10/30/2025 (Estimated)Latest GHRS, BLTE, OGN, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025GHRSGH Research-$0.23N/AN/AN/AN/AN/A11/11/2025Q3 2025BLTEBelite Bio-$0.53N/AN/AN/AN/AN/A11/5/2025Q3 2025CPRXCatalyst Pharmaceuticals$0.50N/AN/AN/A$136.79 millionN/A10/30/2025Q3 2025OGNOrganon & Co.$0.93N/AN/AN/A$1.57 billionN/A8/11/2025Q2 2025BLTEBelite Bio-$0.47-$0.50-$0.03-$0.50N/AN/A8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/A8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.84%N/A2.97%N/ALatest GHRS, BLTE, OGN, and CPRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A23.1523.15CPRXCatalyst PharmaceuticalsN/A6.716.55GHRSGH ResearchN/A29.4929.49OGNOrganon & Co.11.981.651.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%CPRXCatalyst Pharmaceuticals79.22%GHRSGH Research56.90%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%CPRXCatalyst Pharmaceuticals10.40%GHRSGH Research41.60%OGNOrganon & Co.1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableCPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableGHRSGH Research1052.03 million30.38 millionOptionableOGNOrganon & Co.4,000259.97 million254.87 millionNot OptionableGHRS, BLTE, OGN, and CPRX HeadlinesRecent News About These CompaniesOrganon & Co.'s (OGN) "Sell (D+)" Rating Reiterated at Weiss RatingsOctober 10, 2025 | marketbeat.comInvestors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowOctober 8, 2025 | zacks.comBrokerages Set Organon & Co. (NYSE:OGN) Target Price at $17.33October 8, 2025 | americanbankingnews.comOrganon (OGN) Stock Slides as Market Rises: Facts to Know Before You TradeOctober 6, 2025 | zacks.comWill Organon (OGN) Beat Estimates Again in Its Next Earnings Report?October 6, 2025 | zacks.comPublic Employees Retirement System of Ohio Sells 23,948 Shares of Organon & Co. $OGNOctober 6, 2025 | marketbeat.comOrganon & Co. (NYSE:OGN) Receives Average Rating of "Moderate Buy" from AnalystsOctober 3, 2025 | marketbeat.comOrganon & Co. $OGN Shares Acquired by Cantor Fitzgerald Investment Advisors L.P.October 2, 2025 | marketbeat.comOrganon & Co. $OGN Shares Purchased by State of Alaska Department of RevenueOctober 1, 2025 | marketbeat.comOrganon & Co. $OGN Stake Lessened by Sound Income Strategies LLCSeptember 30, 2025 | marketbeat.comDakota Wealth Management Has $151,000 Stock Position in Organon & Co. $OGNSeptember 30, 2025 | marketbeat.comOrganon (OGN) Outperforms Broader Market: What You Need to KnowSeptember 29, 2025 | zacks.comSterneck Capital Management LLC Makes New Investment in Organon & Co. $OGNSeptember 28, 2025 | marketbeat.comRegister Financial Advisors LLC Sells 30,706 Shares of Organon & Co. $OGNSeptember 27, 2025 | marketbeat.comHere's Why Organon (OGN) Fell More Than Broader MarketSeptember 25, 2025 | zacks.comHere is What to Know Beyond Why Organon & Co. (OGN) is a Trending StockSeptember 24, 2025 | zacks.comOrogen Royalties' Exploration Stage Project and Royalty UpdateSeptember 24, 2025 | accessnewswire.comAOrganon (OGN) Stock Dips While Market Gains: Key FactsSeptember 19, 2025 | zacks.comEuropean Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), RespectivelySeptember 19, 2025 | businesswire.comWedmont Private Capital Acquires 106,561 Shares of Organon & Co. $OGNSeptember 19, 2025 | marketbeat.comGilman Hill Asset Management LLC Has $1.97 Million Stock Holdings in Organon & Co. $OGNSeptember 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGHRS, BLTE, OGN, and CPRX Company DescriptionsBelite Bio NASDAQ:BLTE$81.26 +2.00 (+2.52%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$80.87 -0.39 (-0.48%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Catalyst Pharmaceuticals NASDAQ:CPRX$21.26 +0.95 (+4.68%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$21.03 -0.23 (-1.08%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.GH Research NASDAQ:GHRS$14.50 +1.18 (+8.86%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$14.43 -0.07 (-0.51%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Organon & Co. NYSE:OGN$9.55 -0.01 (-0.13%) Closing price 10/15/2025 03:59 PM EasternExtended Trading$9.59 +0.04 (+0.44%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
